UK indefinitely bans puberty blockers for teenagers due to “unacceptable risk”
Puberty blockers for people aged under 18 years with gender dysphoria will be indefinitely banned by the UK Government following…
Genito Urinary System And Sex Hormones
-
-
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment
The US Food and Drug Administration (FDA) has approved Iterum Therapeutics' new drug application (NDA) for ORLYNVAH (sulopenem etzadroxil and…
-
Resolution scores $83m to develop macrophage cell therapies
Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based…
-
After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN
The US Food and Drug Administration (FDA) has converted the accelerated approval for Travere Therapeutics’ Filspari (sparsentan) to full approval…
-
eGenesis scoops $191m for genetically modified pig kidney transplant trial
Investors are rallying around the promise of cross-species transplantation, enabling eGenesis to close a $191m Series D financing round to…
-
Lexicon to face FDA AdCom for Zynquista approval in diabetes and CKD
It looks like Lexicon Pharmaceuticals’ second bid to get US Food and Drug Administration (FDA) approval for Zynquista (sotagliflozin) will…
-
Novo Nordisk’s ocedurenone Phase III flop costs company $816m
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
-
AstraZeneca champions early kidney disease diagnosis with modelling data
AstraZeneca has highlighted both the economic and environmental benefits of implementing early, targeted screening for chronic kidney disease (CKD). CKD…
-
Travere signs $120m licensing deal with Renalys for sparsentan in Asia
Travere Therapeutics has signed a licensing agreement for sparsentan with Japan-based Renalys Pharma for multiple Asian countries. As per the…
-
Novartis eyes label expansion for PNH drug
Novartis plans to discuss the filing of its drug iptacopan in C3 glomerulopathy with global health authorities on the back…
